Ameriprise Financial Inc. Sells 132,854 Shares of Haemonetics Co. (NYSE:HAE)

Ameriprise Financial Inc. lowered its position in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 56.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 102,675 shares of the medical instruments supplier's stock after selling 132,854 shares during the quarter. Ameriprise Financial Inc. owned about 0.20% of Haemonetics worth $8,017,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Boston Trust Walden Corp increased its holdings in shares of Haemonetics by 13.1% during the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock valued at $71,500,000 after acquiring an additional 106,114 shares in the last quarter. Empowered Funds LLC bought a new position in shares of Haemonetics during the fourth quarter valued at $319,000. Pacer Advisors Inc. increased its holdings in shares of Haemonetics by 36.1% during the fourth quarter. Pacer Advisors Inc. now owns 10,104 shares of the medical instruments supplier's stock valued at $789,000 after acquiring an additional 2,680 shares in the last quarter. Norges Bank bought a new position in shares of Haemonetics during the fourth quarter valued at $32,803,000. Finally, Voya Investment Management LLC increased its holdings in shares of Haemonetics by 820.5% during the fourth quarter. Voya Investment Management LLC now owns 316,952 shares of the medical instruments supplier's stock valued at $24,748,000 after acquiring an additional 282,521 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Analyst Ratings Changes

HAE has been the subject of several analyst reports. Raymond James restated a "strong-buy" rating and set a $105.00 price target (down from $115.00) on shares of Haemonetics in a report on Friday, May 9th. Needham & Company LLC reduced their price target on Haemonetics from $104.00 to $84.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Wall Street Zen downgraded Haemonetics from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th. Barrington Research reduced their price objective on Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $100.00 price objective on shares of Haemonetics in a report on Tuesday, May 20th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $97.89.

Haemonetics Stock Performance

Shares of Haemonetics stock traded up $1.86 during trading hours on Tuesday, reaching $67.92. 532,531 shares of the stock traded hands, compared to its average volume of 682,996. The company has a 50 day moving average price of $63.22 and a 200 day moving average price of $70.72. The firm has a market capitalization of $3.26 billion, a price-to-earnings ratio of 26.74, a P/E/G ratio of 1.11 and a beta of 0.32. Haemonetics Co. has a one year low of $55.30 and a one year high of $94.99. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.22 by $0.02. The business had revenue of $330.60 million during the quarter, compared to the consensus estimate of $329.38 million. Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. The business's quarterly revenue was down 3.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.90 EPS. On average, equities research analysts expect that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.